New Product Launch in Coming Years to Fuel Demand for Global Eczema Treatment Market

Eczema is characterized by red skin, rash, and irritation. The affected region of the skin could range from a tiny spot to the whole body. Certain combination of variables, for example, environmental factor, abnormal function of immune system, genetical factor, defect in skin barriers, and exercises can make the skin hyper sensitive. The kinds of dermatitis are treated on the basis of severity, area of rash, and the patient’s medical history. This skin condition is very common in kids and influences adults also. The side effects of eczema vary from individual to individual. Based on the report by Transparency Market Research the market is prognosticated to grow with a moderate speed in coming years. The publication bears the title “Eczema Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.”

The worldwide eczema treatment market is upon expected to be driven by new product launch in coming years. For example, the launch of Sanofi/Regeneron’s dupilumab, a natural treatment for mild-to-severe eczema, is anticipated to shake up the competitive landscape in the near future. Another key driver of the market is the rise of systematic treatments and utilization of topical calcineurin inhibitors. The deeply genericized nature of the eczema treatment is probably going to hinder the development of the market.

As indicated by the National Eczema Association, eczema influences 10% to 20% of youngsters and 1% to 3% of grown-ups in the U.S. consistently. This high prevalence of the ailment is foreseen to make North America, the leading region in the global eczema treatment market. The U.K., Germany, France, and Italy,on the other hand, are driving the market in Europe, which is the second key market for eczema treatment in the world. China and India with their large populations are at the forefront of driving the Asia Pacific market.

Major players working in the eczema treatment market are Astellas Pharma, Sanofi, Anacor Pharmaceuticals Inc., Meda AB, Regeneron Pharmaceuticals Inc., GlaxoSmithKline, Pfizer Inc., and AstraZeneca.

Request a Brochure of the Report @

Leave a Reply